SCHEMBL1320344

SCHEMBL1320344

O=C(/C=C/c1ccc(/C=C/C(=O)c2ccccc2)c(F)c1)NO

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 10/20 0.72
HDAC1 Q13547 10/20 0.72
HDAC2 Q92769 10/20 0.72
HDAC3 O15379 9/20 0.72
HDAC8 Q9BY41 9/20 0.72
HDAC6 Q9UBN7 9/20 0.72
HDAC7 Q8WUI4 8/20 0.72
HDAC10 Q969S8 8/20 0.72
HDAC11 Q96DB2 8/20 0.72
HDAC9 Q9UKV0 8/20 0.72
HDAC5 Q9UQL6 8/20 0.72
MAOB P27338 2/20 0.53
PLIN1 O60240 1/20 0.53
LMNA P02545 1/20 0.53
BCHE P06276 1/20 0.53
MAPT P10636 1/20 0.53
TNFRSF1A P19438 1/20 0.53
ACHE P22303 1/20 0.53
RECQL P46063 1/20 0.53
PLIN5 Q00G26 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1320011 1.00 HDAC4 (0.72) HDAC4HDAC1HDAC2HDAC3HDAC8
SCHEMBL1320345 1.00 HDAC4 (0.72) HDAC4HDAC1HDAC2HDAC3HDAC8
SCHEMBL1320010 1.00 HDAC4 (0.72) HDAC4HDAC1HDAC2HDAC3HDAC8
SCHEMBL1322603 0.90 TNFRSF1A (0.61) HDAC4HDAC1HDAC2HDAC3HDAC8
SCHEMBL1322602 0.90 TNFRSF1A (0.61) HDAC4HDAC1HDAC2HDAC3HDAC8
SCHEMBL1320083 0.89 HDAC8 (0.62) HDAC4HDAC1HDAC2HDAC3HDAC8
SCHEMBL1320084 0.89 HDAC8 (0.62) HDAC4HDAC1HDAC2HDAC3HDAC8
SCHEMBL1319923 0.88 HDAC1 (0.56) HDAC4HDAC1HDAC2HDAC3HDAC8
SCHEMBL1322218 0.88 MAPT (0.58) HDAC4HDAC1HDAC2HDAC3HDAC8
SCHEMBL1319922 0.88 HDAC1 (0.56) HDAC4HDAC1HDAC2HDAC3HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814850-B9 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2015-02-25 EP claimed
EP-1814850-B1 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2013-07-03 EP claimed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US claimed
US-7803800-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2010-09-28 US claimed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US claimed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US claimed
EP-1814850-B9 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2015-02-25 EP disclosed
EP-1814850-B1 NEW HISTONE DEACETYLASES INHIBITORS DAC SRL (IT) 2013-07-03 EP disclosed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US disclosed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US disclosed
US-8058273-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2011-11-15 US disclosed
US-7803800-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2010-09-28 US disclosed
US-7803800-B2 Histone deacetylases inhibitors DAC S.R.L. (IT) 2010-09-28 US disclosed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US disclosed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US disclosed
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2010-09-23 US disclosed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US disclosed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US disclosed
US-20080096889-A1 Histone Deacetylases Inhibitors GENEXTRA S.P.A. (IT) 2008-04-24 US disclosed
WO-2006037761-A1 NEW HISTONE DEACETYLASES INHIBITORS DAC S.R.L. (IT) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240660-A1 NEW HISTONE DEACETYLASES INHIBITORS HDAC1, HDAC3, HDAC11 HDAC4 11/4885HDAC1 1/4885HDAC2 4/4885
US-20080096889-A1 Histone Deacetylases Inhibitors HDAC1, HDAC3, HDAC11 HDAC4 10/4885HDAC1 1/4885HDAC2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.